Targeting hypoxia for sensitization of tumors to radio- and chemotherapy

Current Cancer Drug Targets

Volumn 13, Issue 6, 2013, Pages 670-685

  Ghattass, Khaled ^a   Assah, Rana ^b   El Sabban, Marwan ^a   Gali Muhtasib, Hala ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b NEW YORK UNIVERSITY ABU DHABI   (United Arab Emirates)

Author keywords

Bioreductive drugs; Cancer stem cells; Epithelial to mesenchymal transition; Hypoxia inducible factor; Metastasis; Radiosensitizers

Indexed keywords

1,4 BIS 5,8 DIHYDROXY ANTHRACENE 9, 10 DIONE; 2 BENZOYL 3 PHENYL 6,7 DICHLOROQUINOXALINE 1,4 DIOXIDE; 4 [3 (2 NITRO 1 IMIDAZOLYL) PROPYLAMINO] 7 CHLOROQUINOLINE HYDROCHLORIDE; 4 [BIS (2 CHLOROETHYL) OXIDOAMINO] PHENYLALANINE; 4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; ANTINEOPLASTIC AGENT; APAZIQUONE; BANOXANTRONE; DIETHYLAMINE; DORANIDAZOLE; DOXORUBICIN; E1A ASSOCIATED P300 PROTEIN; ETANIDAZOLE; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA 107; MISONIDAZOLE; MITOMYCIN; NSC 709257; PACLITAXEL; PORFIROMYCIN; PR 104; PROTEIN KINASE B; PROTEIN P53; SN 29730; TH 302; TIRAPAZAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ANGIOGENESIS; ANUS CANCER; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOSENSITIZATION; CYTOTOXICITY; DRUG MEGADOSE; HEAD AND NECK CARCINOMA; HUMAN; HYPOXIA; IONIZING RADIATION; LUNG CANCER; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; RADIOSENSITIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR HYPOXIA; TUMOR RESISTANCE; UTERINE CERVIX CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEDIFFERENTIATION; CELL HYPOXIA; DRUG RESISTANCE, NEOPLASM; EVIDENCE-BASED MEDICINE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; RADIATION-SENSITIZING AGENTS;

EID: 84888085891     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/15680096113139990004     Document Type: Article

References (133)

1. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100 (1), 57-70.
2. Lunt, S. J.; Chaudary, N.; Hill, R. P. The tumor microenvironment and metastatic disease. Clin. Exp. Metastasis. 2009, 26 (1), 19-34.
3. Vaupel, P.; Kallinowski, F.; Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer. Res. 1989, 49 (23), 6449-6465.
4. Denko, N. C.; Fontana, L. A.; Hudson, K. M.; Sutphin, P. D.; Raychaudhuri, S.; Altman, R.; Giaccia, A. J. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 2003, 22 (37), 5907-5914.
5. Kim, J. W.; Gao, P.; Dang, C. V. Effects of hypoxia on tumor metabolism. Cancer Metastasis Rev. 2007, 26 (2), 291-298.
6. McDonnell, C.O.; Hill, A. D. K.; McNamara, D. A.; Walsh, T. N.; Bouchier-Hayes, D. J. Tumour micrometastases: the influence of angiogenesis. Eur. J. Surg. Oncol. 2000, 26 (2), 105-115.
7. Baluk, P.; Morikawa, S.; Haskell, A.; Mancuso, M.; McDonald, D. M. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 2003, 163 (5), 1801-1815.
8. Sullivan, R.; Graham, C. H. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev. 2007, 26 (2), 319-331.
9. Favaro, E.; Lord, S.; Harris, A. L.; Buffa, F. M. Gene expression and hypoxia in breast cancer. Genome Med. 2011, 3 (8), 55.
10. Mehlen, P.; Puisieux, A. Metastasis: a question of life or death. Nat. Rev. Cancer. 2006, 6 (6), 449-458.
11. Fyles, A.; Milosevic, M.; Hedley, D.; Pintilie, M.; Levin, W.; Manchul, L.; Hill, R. P. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J. Clin. Oncol. 2002, 20 (3), 680-687.
12. Cairns, R. A.; Kalliomaki, T.; Hill, R. P. Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Res. 2001, 61 (24), 8903-8308.
13. Koch, U.; Krause, M.; Baumann, M. Cancer stem cells at the crossroads of current cancer therapy failures--radiation oncology perspective. Semin. Cancer Biol. 2010, 20 (2), 116-124.
14. Wilson, W. R.; Hay, M. P. Targeting hypoxia in cancer therapy. Nature Reviews Cancer 2011, 11, 393-410.
15. Covello, K. L.; Kehler, J.; Yu, H.; Gordan, J. D.; Arsham, A. M.; Hu, C. J.; Labosky, P. A.; Simon, M. C.; Keith, B. HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 2006, 20 (5), 557-570.
16. Chen, J.; Imanaka, N.; Chen, J.; Griffin, J. D. Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br. J. Cancer 2010, 102 (2), 351-360.
17. Wind, N. S.; Holen, I. Multidrug resistance in breast cancer: from in vitro models to clinical studies. Int. J. Breast Cancer 2011, 2011, 967419.
18. Hill, R. P.; Marie-Egyptienne, D. T.; Hedley, D. W. Cancer stem cells, hypoxia and metastasis. Semin. Radiat. Oncol. 2009, 19 (2), 106-111.
19. Rockwell, S.; Dobrucki, I. T.; Kim, E. Y.; Marrison, S. T.; Vu, V. T. Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr. Mol. Med. 2009, 9 (4), 442-458.
20. Wouters, B. G.; Weppler, S. A.; Koritzinsky, M.; Landuyt, W.; Nuyts, S.; Theys, J.; Chiu, R. K.; Lambin, P. Hypoxia as a target for combined modality treatments. Eur. J. Cancer 2002, 38 (2), 240-257.
21. Oronsky, B. T.; Knox, S. J.; Scicinski, J. Six degrees of separation: the oxygen effect in the development of radiosensitizers. Transl. Oncol. 2011, 4 (4), 189-198.
22. Brown, J. M. Imaging tumor sensitivity to a bioreductive prodrug: two for the price of one! Clin. Cancer. Res. 2012, 18 (6), 1487-1489.
23. Stratford, I. J.; Williams, K. J.; Cowen, R. L.; Jaffar, M. Combining bioreductive drugs and radiation for the treatment of solid tumors. Semin. Radiat. Oncol. 2003, 13 (1), 42-52.
24. Wang, Y.; Liu, Y.; Malek, S. N.; Zheng, P.; Liu, Y. Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 2011, 8 (4), 399-411.
25. Ruan, K.; Song, G.; Ouyang, G. Role of hypoxia in the hallmarks of human cancer. J. Cell. Biochem. 2009, 107 (6), 1053-1062.
26. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3 (10), 721-732.
27. Pasanen, A.; Heikkilä, M.; Rautavuoma, K.; Hirsilä, M.; Kivirikko, K. I.; Myllyharju, J. Hypoxia-inducible factor (HIF)-3alpha is subject to extensive alternative splicing in human tissues and cancer cells and is regulated by HIF-1 but not HIF-2. Int. J. Biochem. Cell. Biol. 2010, 42 (7), 1189-1200.
28. Pugh, C. W.; Ratcliffe, P. J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 2003, 9 (6), 677-684.
29. Lando, D.; Peet, D. J.; Gorman, J. J.; Whelan, D. A.; Whitelaw, M. L.; Bruick, R. K. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes. Dev. 2002, 16 (12), 1466-1471.
30. Kenneth, N. S.; Mudie, S.; van Uden, P.; Rocha, S. SWI/SNF regulates the cellular response to hypoxia. J. Biol. Chem. 2009, 284 (7), 4123-4131.
31. Semenza, G. L. HIF-1 and mechanisms of hypoxia sensing. Curr. Opin. Cell. Biol. 2001, 13 (2), 167-171.
32. Ravi, R.; Mookerjee, B.; Bhujwalla, Z. M.; Sutter, C. H.; Artemov, D.; Zeng, Q.; Dillehay, L. E.; Madan, A.; Semenza, G. L.; Bedi, A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes. Dev. 2000, 14 (1), 34-44.
33. Yamakuchi, M.; Lotterman, C. D.; Bao, C.; Hrubane, R. H.; Karime, B.; Mendell, J. T.; Husof, D.; Lowensteina, C. J. P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc. Natl. Acad. Sci. USA. 2010, 107 (14), 6334-6339.
34. Cascio, S.; D'Andrea, A.; Ferla, R.; Surmacz, E.; Gulotta, E.; Amodeo, V.; Bazan, V.; Gebbia, N.; Russo, M. miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells. J. Cell. Physiol. 2010, 224 (1), 242-249.
35. Kulshreshtha, R. A microRNA signature of hypoxia. Mol. Cell. Biol. 2007, 27 (5), 1859-1867.
36. Wouters, B. G.; Koritzinsky, M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat. Rev. Cancer 2008, 8 (11), 851-864.
37. Sang, N.; Stiehl, D. P.; Bohensky, J.; Leshchinsky, I.; Srinivas, V.; Caro, J. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J. Biol. Chem. 2003, 278 (16), 14013-14019.
38. Keith, B.; Johnson, R. S.; Simon, M. C. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 2012, 12 (1), 9-22.
39. Koh, M. Y.; Darnay, B. G.; Powis, G. Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation. Mol. Cell. Biol. 2008, 28 (23), 7081-7095.
40. Xu, J.; Wang, B.; Xu, Y.; Sun, L.; Tian, W.; Shukla, D.; Barod, R.; Grillari, J.; Grillari-Voglauer, R.; Maxwell, P. H.; Esteban, M. A. Epigenetic regulation of HIF-1alpha in renal cancer cells involves HIF-1alpha/2alpha binding to a reverse hypoxia-response element. Oncogene 2012, 31 (8), 1065-1072.
41. Xiang, Z. L.; Zeng, Z. C.; Fan, J.; Tang, Z. Y.; He, J.; Zeng H. Y.; Chang, J. Y. The expression of HIF-1alpha in primary hepatocellular carcinoma and its correlation with radiotherapy response and clinical outcome. Mol. Biol. Rep. 2012, 39 (2), 2021-2029.
42. Ban, H.S.; Uto, Y.; Nakamura, H. Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004 -2010). Expert Opin. Ther. Pat. 2011, 21 (2), 131-146.
43. Koh, M. Y.; Spivak-Kroizman, T.; Venturini, S.; Welsh, S.; Williams, R.R.; Kirkpatrick, D.L.; Powis, G. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol. Cancer Ther. 2008, 7 (1), 90-100.
44. Palayoor, S. T.; Mitchell, J. B.; Cerna, D.; Degraff, W.; John-Aryankalayil, M.; Coleman, C. N.; PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells. Int. J. Cancer 2008, 123 (10), 2430-2437.
45. Jacoby, J. J.; Erez, B.; Korshunova MV; Williams, R. R.; Furutani, K.; Takahashi, O.; Kirkpatrick, L.; Lippman, S. M.; Powis, G.; O'Reilly, M. S.; Herbst, R. S. Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice. J. Thorac. Oncol. 2010, 5 (7), 940-949.
46. Singh-Gupta, V.; Zhang, H.; Banerjee, S.; Kong, D.; Raffoul, J. J.; Sarkar, F. H.; Hillman, G. G.; Radiation-induced HIF-1alpha cell survival pathway is inhibited by soy isoflavones in prostate cancer cells. Int. J. Cancer 2009, 124 (7), 1675-1684.
47. Hahnel, A.; Wichmann, H.; Kappler, M.; Kotzsch, M.; Vordermark, D.; Taubert, H.; Bache, M. Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. Radiat. Oncol. 2010, 5, 82.
48. Yang, W.; Sun, T.; Cao, J.; Fan, S. Hypoxia-inducible factor-1alpha downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and enhances radiosensitivity in chemical hypoxic human hepatoma SMMC-7721 cells. Cancer Biother. Radiopharm. 2011, 26 (5), 565-571.
49. Huang, Y.; Yuhua Huang, Yu J.; Yan, C.; Hou, J.; Pu, J.; Zhang, G.; Fu, Z.; Wang, X. Effect of small interfering RNA targeting hypoxia-inducible factor-1alpha on radiosensitivity of PC3 cell line. Urology 2012, 79 (3),744 e17-e24.
50. Harada, H.; Hiraoka, M. Hypoxia-inducible factor 1 in tumor radioresistance. Curr. R. Signal Transd. T. 2010, 5, 188-196.
51. Acker, T.; Diez-Juan, A.; Aragones, J.; Tjwa, M.; Brusselmans, K.; Moons, L.; Fukumura, D.; Moreno-Murciano, M. P.; Herbert, J. M.; Burger, A.; Riedel, J.; Elvert, G.; Flamme, I.; Maxwell, P. H.; Collen, D.; Dewerchin, M.; Jain, R. K.; Plate, K. H.; Carmeliet, P. Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell 2005, 8 (2), 131-141.
52. Bertout, J. A.; Majmundar, A. J.; Gordan, J. D.; Lam, J. C.; Ditsworth, D.; Keith, B.; Brown, E. J.; Nathanson, K. L.; Simon, M. C. HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc. Natl. Acad. Sci. U S A. 2009, 106 (34), 14391-14396.
53. Turchi, L.; Aberdam, E.; Mazure, N.; Pouysségur, J.; Deckert, M.; Kitajima, S.; Aberdam, D.; Virolle, T. Hif-2alpha mediates UV-induced apoptosis through a novel ATF3-dependent death pathway. Cell Death Differ. 2008, 15 (9), 1472-1480.
54. Bhatt, R. S.; Landis, D. M.; Zimmer, M.; Torregrossa, J.; Chen, S.; Sukhatme, V. P.; Iliopoulos, O.; Balk, S.; Bubley, G. J. Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor. BJU. Int. 2008, 102 (3), 358-363.
55. Al-Hajj, M.; Wicha, M. S.; Benito-Hernandez, A.; Morrison, S. J.; Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U S A. 2003, 100 (7), 3983-3988.
56. Moncharmont, C.; Levy, A.; Gilormini, M.; Bertrand, G.; Chargari, C.; Alphonse, G.; Ardail, D.; Rodriguez-Lafrasse, C.; Magné, N. Targeting a cornerstone of radiation resistance: Cancer stem cell. Cancer Lett. 2012, 322 (2), 139-147.
57. Lin, Q.; Lee, Y. J.; Yun, Z. Differentiation arrest by hypoxia. J. Biol. Chem. 2006, 281 (41), 30678-30683.
58. Tsai, C. C.; Chen, Y. J.; Yew, T. L.; Chen, L. L.; Wang, J. Y.; Chiu, C. H.; Hung, S. C. Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST. Blood 2011, 117 (2), 459-469.
59. Cunningham, L.A.; Candelario, K.; Li, L. Roles for HIF-1alpha in neural stem cell function and the regenerative response to stroke. Behav. Brain Res. 2012, 227 (2), 410-417.
60. Mazumdar, J.; O'Brien, W. T.; Johnson, R. S.; LaManna, J. C.; Chavez, J. C.; Klein, P. S.; Simon, M. C. O2 regulates stem cells through Wnt/beta-catenin signalling. Nat. Cell Biol. 2010, 12 (10), 1007-1013.
61. Yang, M. H.; Wu, M. Z.; Chiou, S. H.; Chen, P. M.; Chang, S.Y.; Liu, C. J.; Teng, S.C.; Wu, K. J. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat. Cell Biol. 2008, 10 (3), 295-305.
62. Vesuna, F.; Lisok, A.; Kimble, B.; Raman, V.; Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression. Neoplasia 2009, 11 (12), 1318-1328.
63. Bao, S.; Wu, Q.; McLendon, R. E.; Hao, Y.; Shi, Q.; Hjelmeland, A. B.; Dewhirst, M. W.; Bigner, D. D.; Rich, J. N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444 (7120), 756-760.
64. Woodward, W. A.; Chen, M. S.; Behbod, F.; Alfaro, M. P.; Buchholz, T.A.; Rosen, J. M. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc. Natl. Acad. Sci. 2007, 104 (2), 618-623.
65. Lagadec, C.; Vlashi, E.; Della Donna, L.; Dekmezian, C.; Pajonk, F. Radiation-induced reprogramming of breast cancer cells. Stem Cells 2012, 30 (5), 833-844.
66. Cheng, W.; Liu, T.; Wan, X.; Gao, Y.; Wang, H. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS 2012, 279 (11), 2047-2059.
67. Chistiakov, D. A.; Chekhonin V. P. Contribution of microRNAs to radio-and chemoresistance of brain tumors and their therapeutic potential. Eur. J. Pharmacol. 2012, 684 (1-3), 8-18.
68. Moreb, J. S. Aldehyde dehydrogenase as a marker for stem cells. Curr. Stem. Cell Res. Ther. 2008, 3 (4), 237-246.
69. Croker, A. K.; Allan, A. L. Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDH(hi)CD44 (+) human breast cancer cells. Breast Cancer Res. Treat. 2012, 133 (1), 75-87.
70. Pelicci, P. G.; Dalton, P.; Orecchia, R. Heating cancer stem cells to reduce tumor relapse. Breast Cancer Res. 2011. 13 (3), 305.
71. Rontgen, W.C. On a New Kind of Rays. Science 1896, 3 (59), 227-231.
72. Harada, H. How can we overcome tumor hypoxia in radiation therapy? J. Radiat. Res. 2011, 52 (5), 545-556.
73. Brown, J. M.; Wilson, W. R. Exploiting tumour hypoxia in cancer treatment. Nat.Rev.Cancer 2004, 4 (6), 437-447.
74. Bindra, R. S.; Crosby, M. E.; Glazer, P. M. Regulation of DNA repair in hypoxic cancer cells. Cancer Metastasis Rev. 2007, 26 (2), 249-260.
75. Moeller, B. J.; Moeller B.J.; Cao Y; Li C.Y., Dewhirst M.W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004, 5 (5), 429-441.
76. Moeller, B. J.; Dewhirst, M.W. HIF-1 and tumour radiosensitivity. Br. J.Cancer 2006, 95 (1) 1-5.
77. Moeller, B. J., Moeller, B. J.; Dreher, M. R.; Rabbani, Z. N.; Schroeder, T.; Cao, Y.; Li, C. Y.; Dewhirst, M. W. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 2005, 8 (2), 99-110.
78. Coleman, C. N. Hypoxic cell radiosensitizers: expectations and progress in drug development. Int. J. Radiat. Oncol. Biol. Phys. 1985, 11 (2), 323-329.
79. Yahiro, T.; Masui, S.; Kubota, N.; Yamada, K.; Kobayashi, A.; Kishii, K. Effects of hypoxic cell radiosensitizer doranidazole (PR-350) on the radioresponse of murine and human tumor cells in vitro and in vivo. J. Radiat. Res. 2005, 46 (3), 363-372.
80. Abe, C., Uto, Y.; Nakae, T.; Shinmoto, Y.; Sano, K.; Nakata, H.; Teraoka, M.; Endo, Y.; Maezawa, H.; Masunaga, S.; Nakata, E.; Hori, H. Evaluation of the in vivo radiosensitizing activity of etanidazole using tumor-bearing chick embryo. J. Radiat. Res. 2011, 52 (2), 208-214.
81. Egeland, T.A., Gaustad, J. V.; Vestvik, I. K.; Benjaminsen, I. C.; Mathiesen, B.; Rofstad, E. K. Assessment of fraction of radiobiologically hypoxic cells in human melanoma xenografts by dynamic contrast-enhanced MRI. Magn. Reson. Med. 2006, 55 (4), 874-882.
82. Yu, C. X. Intensity-modulated arc therapy with dynamic multileaf collimation: an alternative to tomotherapy. Phys. Med. Biol. 1995, 40 (9), 1435-1449.
83. Oronsky, B. T.; Knox, S. J.; Scicinski, J. J. Is Nitric Oxide (NO) the Last Word in Radiosensitization? A. Review. Transl. Oncol. 2012, 5 (2), 66-71.
84. J. P., H. Evidence for the use of low dose nitric oxide in the treatments of rising PSA associated with biochemical failure following radical prostatectomy. J. Urol. 2003, 169 (Suppl. S), 1082.
85. De Ridder, M.; Verellen, D.; Verovski, V.; Storme, G.; Hypoxic tumor cell radiosensitization through nitric oxide. Nitric Oxide 2008, 19 (2), 164-169.
86. Cook, T., Wang, Z.; Alber, S.; Liu, K.; Watkins, S. C.; Vodovotz, Y.; Billiar, T. R.; Blumberg, D. Nitric oxide and ionizing radiation synergistically promote apoptosis and growth inhibition of cancer by activating p53. Cancer Res. 2004, 64 (21), 8015-8021.
87. Howard-Flanders, P. Effect of nitric oxide on the radiosensitivity of bacteria. Nature 1957, 180, 1191-1192.
88. Mitchell, J. B.; Wink, D. A.; DeGraff, W.; Gamson, J.; Keefer, L. K.; Krishna, M. C. Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res. 1993, 53 (24), 5845-5848.
89. Wardman, P., Rothkamm, K.; Folkes, L. K.; Woodcock, M.; Johnston, P. J. Radiosensitization by nitric oxide at low radiation doses. Radiat. Res. 2007, 167 (4), 475-484.
90. Mohindra, J. K.; Rauth, A. M. Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells. Cancer Res. 1976, 36, 930-936.
91. McKeown, S. R.; Cowen, R. L.; Williams, K. J. Bioreductive drugs: from concept to clinic. Clin. Oncol. 2007, 19 (6), 427-442.
92. Peters, K. B.; B, J. M. Tirapazamine: a hypoxia-activatedtopoisomerase II poison. Cancer Res. 2002, 62, 5248-5253.
93. Patterson, L. H. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Met. Rev. 1993, 12 (2), 119-134.
94. Taylor, Y. C.; Rauth, A. M. Sulphydryls, ascorbate and oxygen as modifiers of the toxicity and metabolism of misonidazole in vitro. Br. J. Cancer 1980, 41 (6), 892-900.
95. Lavaggi, M. L.; Cabrera, M.; Pintos, C.; Arredondo, C.; Pachón, G.; Rodríguez, J.; Raymondo, S.; Pacheco, J. P.; Cascante, M.; Olea-Azar, C.; López de Ceráin, A.; Monge, A.; Cerecetto, H.; González, M. Novel Phenazine 5,10-Dioxides Release OH in Simulated Hypoxia and Induce Reduction of Tumour Volume In Vivo. ISRN Pharmacol. 2011, 314209.
96. Ahn, G. O.; Botting, K. J.; Patterson, A. V.; Ware, D. C.; Tercel, M.; Wilson, W. R. Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator. Biochem. Pharmacol. 2006, 71 (12), 1683-1694.
97. Parker, L. L.; Lacy, S. M.; Farrugia, L. J.; Evans, C.; Robins, D. J.; O'Hare, C.C.; Hartley, J. A.; Jaffar, M.; Stratford, I. J. A novel design strategy for stable metal complexes of nitrogen mustards as bioreductive prodrugs. J. Med. Chem. 2004, 47 (23), 5683-5689.
98. Branzei, D.; Foiani, M. Maintaining genome stability at the replication fork. Nat. Rev. Mol. Cell Biol. 2010, 11 (3), 208-219.
99. Evans, J. W.; Chernikova, S. B.; Kachnic, L. A.; Banath, J. P.; Sordet, O.; Delahoussaye, Y. M.; Treszezamsky, A.; Chon, B. H.; Feng, Z.; Gu, Y.; Wilson, W. R.; Pommier, Y.; Olive, P. L.; Powell, S. N.; Brown, J. M. Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells. Cancer Res. 2008, 68 (1), 257-265.
100. Gu, Y.; Patterson, A. V.; Atwell, G. J.; Chernikova, S. B.; Brown, J. M.; Thompson, L. H.; Wilson, W. R. Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Mol. Cancer Ther. 2009, 8 (6), 1714-1723.
101. Brown, J. M. The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res. 1999, 59 (23), 5863-5870.
102. Rischin, D.; Peters, L.; Fisher, R.; Macann, A.; Denham, J.; Poulsen, M.; Jackson, M.; Kenny, L.; Penniment, M.; Corry, J.; Lamb, D.; McClure, B. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J. Clin. Oncol. 2005, 23 (1), 79-87.
103. Rischin, D.; Peters, L. J.; O'Sullivan, B.; Giralt, J.; Fisher, R.; Yuen, K.; Trotti, A.; Bernier, J.; Bourhis, J.; Ringash, J.; Henke, M.; Kenny, L. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J. Clin. Oncol. 2010, 28 (18), 2989-2995.
104. Chinje, E. C., Cowen, R. L.; Feng, J.; Sharma, S. P.; Wind, N. S.; Harris, A. L.; Stratford, I. J. Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro. Mol. Pharmacol. 2003, 63 (6), 1248-1255.
105. Singh, S.; Gupta, A. K. Nitric oxide: role in tumour biology and iNOS/NO-based anticancer therapies. Cancer Chemother Pharmacol. 2011, 67 (6), 1211-1224.
106. Cowen, R. L. Adenoviral delivery of inducible nitric oxide synthase (NOS II) enhances AQ4 N/radiation cytotoxicity within hypoxic tumor cells. AACR Meeting 2005, abstracts 314-A.
107. McKeown, S. R.; Hejmadi, M. V.; McIntyre, I. A,; McAleer, J. J.; Patterson, L. H. AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br. J. Cancer 1995, 72 (1), 76-81.
108. Patterson, L. H.; McKeown, S. R.; Ruparelia, K.; Double, J. A.; Bibby, M. C.; Cole, S.; Stratford, I. J. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. Br. J. Cancer 2000, 82 (12), 1984-1990.
109. McKeown, S. R. Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation. Br. J. Cancer Suppl. 1996, 27, S39-S42.
110. Hejmadi, M. V.; McKeown, S. R.; Friery, O. P.; McIntyre, I. A.; Patterson, L. H.; Hirst, D. G. DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells. Br. J. Cancer 1996, 73 (4), 499-505.
111. Tercel, M.; Atwell, G. J.; Yang, S.; Ashoorzadeh, A.; Stevenson, R. J.; Botting, J.; Gu, Y.; Mehta, S. Y.; Denny, W. A.; Wilson, W. R.; Prujin, F. B. Selective treatment of hypoxic tumor cells in vivo: phosphate pre-prodrugs of nitro analogues of the duocarmycins. Angew. Chem. Int. Ed. Engl. 2011, 50 (11), 2606-2609.
112. Roberts, K. B.; Urdaneta, N.; Vera, R.; Vera, A.; Gutierrez, E.; Aguilar, Y.; Ott, S.; Medina, I.; Sempere, P.; Rockwell, S.; Sartorelli, A. C.; Fischer, D. B.; Fischer, J. J. Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous-cell carcinoma of the cervix. Int. J. Cancer 2000, 90 (4), 206-223.
113. Rewari, A.N.; Haffty, B. G.; Wilson, L. D.; Son, Y. H.; Joe, J. K.; Ross, D. A.; Papac, R. J.; Sasaki, C. T.; Fischer, J. J. Postoperative concurrent chemoradiotherapy with mitomycin in advanced squamous cell carcinoma of the head and neck: results from three prospective randomized trials. Cancer J. 2006, 12 (2), 123-129.
114. Flam, M.; John, M.; Pajak, T. F.; Petrelli, N.; Myerson, R.; Doggett, S.; Quivey, J.; Rotman, M.; Kerman, H.; Coia, L.; Murray K. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J. Clin. Oncol. 1996, 14 (9), 2527-2539.
115. Candelaria, M.; Garcia-Arias, A.; Cetina, L.; Dueñas-Gonzalez, A. Radiosensitizers in cervical cancer. Cisplatin and beyond. Radiat. Oncol. 2006, 1, 15.
116. Fracasso, P. M.; Sartorelli, A. C. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells. Cancer Res. 1986, 46 (8), 3939-3944.
117. Rockwell, S.; Keyes, S. R.; Sartorelli, A. C. Preclinical studies of porfiromycin as an adjunct to radiotherapy. Radiat. Res. 1988, 116 (1), 100-113.
118. Gali-Muhtasib, H. U.; Haddadin, M. J.; Rahhal, D. N.; Younes, I. H. Quinoxaline 1,4-dioxides as anticancer and hypoxia-selective drugs. Oncol. Rep. 2001, 8 (3), 679-684.
119. Haykal, J.; Geara, F.; Haddadin, M. J.; Smith, C. A.; Gali-Muhtasib, H. U. The radiosensitizer 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide induces DNA damage in EMT-6 mammary carcinoma cells. Radiat. Oncol. 2009, 4, 25.
120. Itani, W.; Geara, F.; Haykal, J.; Haddadin, M. J.; Gali-Muhtasib, H. U. Radiosensitization by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide under oxia and hypoxia in human colon cancer cells. Radiat. Oncol. 2007, 2, 1.
121. Harakeh, S.; Diab-Assef, M.; El-Sabban, M.; Haddadin, M. J.; Gali-Muhtasib, H. U. Inhibition of proliferation and induction of apoptosis by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide in adult T-cell leukemia cells. Chem. Biol. Interact. 2004, 148 (3), 101-113.
122. El-Khatib, M.; Geara, F.; Haddadin, M. J.; Gali-Muhtasib, H. U. Cell death by the quinoxaline dioxide DCQ in human colon cancer cells is enhanced under hypoxia and is independent of p53 and p21. Radiat. Oncol. 2010, 5, 107.
123. Junnotula, V.; Sarkar, U.; Sinha, S.; Gates, K. S. Initiation of DNA strand cleavage by 1,2,4-benzotriazine 1,4-dioxide antitumor agents: mechanistic insight from studies of 3-methyl-1,2, 4-benzotriazine 1,4-dioxide. J. Am. Chem. Soc. 2009, 131 (3), 1015-1024.
124. Cowen, R.L.; Patterson, A. V.; Telfer, B. A.; Airley, R. E.; Hobbs, S.; Phillips, R. M.; Jaffar, M.; Stratford, I; Williams K. J. Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts. Mol. Cancer Ther. 2003, 2 (9), 901-909.
125. Gan, Y.; Mo, Y.; Kalns, J. E.; Lu, J.; Danenberg, K.; Danenberg, P.; Wientjes, M. G.; Au J. L. Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors. Clin. Cancer Res. 2001, 7 (5), 1313-1319.
126. Raleigh, S. M.; Wanogho, E.; Burke, M. D.; McKeown, S. R.; Patterson, L. H. Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug. Int. J. Radiat. Oncol. Biol. Phys. 1998, 42 (4), 763-767.
127. Patterson, L. H.; McKeown, S. R.; Robson, T.; Gallagher, R.; Raleigh, S. M.; Orr, S. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. Anticancer Drug Des. 1999, 14 (6), 473-486.
128. Rivera, S. P.; Wang, F.; Saarikoski, S. T.; Taylor, R. T.; Chapman, B.; Zhang, R.; Hankinson, O. A novel promoter element containing multiple overlapping xenobiotic and hypoxia response elements mediates induction of cytochrome P4502S1 by both dioxin and hypoxia. J. Biol. Chem. 2007, 282 (15), 10881-10893.
129. Nishida, C. R.; Ortiz de Montellano, P. R. Reductive heme-dependent activation of the n-oxide prodrug AQ4N by nitric oxide synthase. J. Med. Chem. 2008, 51 (16), 5118-5120.
130. Tendler, D. S.; Bao, C.; Wang, T.; Huang, E. L.; Ratovitski, E. A.; Pardoll, D. A.; Lowenstein, C. J. Intersection of interferon and hypoxia signal transduction pathways in nitric oxide-induced tumor apoptosis. Cancer Res. 2001, 61 (9), 3682-3688.
131. Mateo, J.; García-Lecea, M.; Cadenas, S.; Hernández, C.; Moncada, S. Regulation of hypoxia-inducible factor-1alpha by nitric oxide through mitochondria-dependent and-independent pathways. Biochem. J. 2003, 376 (Pt 2), 537-544.
132. Lou, J. J.; Chua, Y. L.; Chew, E. H.; Gao, J.; Bushell, M.; Hagen, T. Inhibition of hypoxia-inducible factor-1alpha (HIF-1alpha) protein synthesis by DNA damage inducing agents. PLoS One 2010, 5 (5), e10522.
133. Zhang, J.; Cao, J.; Weng, Q.; Wu, R.; Yan, Y.; Jing, H.; Zhu, H.; He, Q.; Yang, B. Suppression of hypoxia-inducible factor 1alpha (HIF-1alpha) by tirapazamine is dependent on eIF2alpha phosphorylation rather than the mTORC1/4E-BP1 pathway. PLoS One 2010, 5(11), e13910.